title: [Effect of subconjunctival bevacizumab on corneal neovascularization and reepithelization 25 days after chemical burn].
abstract: OBJECTIVE
  To evaluate the effect of subconjunctival bevacizumab in an experimental model of neovascularization in rabbit cornea. Determine its effect on vessels extension, inflammation, epithelialization of the cornea and whether the evaluation method used is appropriate to compare neovascular models.
  
  
  METHODS
  Experimental, prospective, randomized, blinded study in twenty rabbits subjected to chemical trauma with sodium hydroxide at 1N divided into two groups. The study group received subconjunctival injection of 0.15 ml (3.75 mg) of bevacizumab and was compared with the control group that received subconjunctival injection of 0.15 ml saline solution. After 25 days, digital photographic analysis was performed to assess the vessel's extension and inflammation/diameter according to pre-established criteria. Histopathology of the cornea, which evaluated the state of the epithelium and the number of polymorphonuclear cells was also studied.
  
  
  RESULTS
  The length of the neovessels was greater in the control group compared to the study group (P=<0.001). There was no difference in inflammation/vessel diameter between groups. Histopathology analysis showed that there was no difference between groups for the variables state of the epithelium and number of polymorphonuclear cells. The concordance analysis for the variable extension of the vessels and the variable inflammation/vessel diameter was estimated with Kappa coefficients of 0.705 and 0.500 respectively, indicating a good level of agreement in different evaluations and validating the method.
  
  
  CONCLUSIONS
  The experimental model is adequate and can be reproduced to evaluate other drugs in the cornea. Bevacizumab inhibit the neovessels' growth but was not effective in preventing the inflammatory response. The drug did not delay the reepithelialization of the cornea.
authors.affiliation: Hospital Universitário Evangélico de Curitiba e da Faculdade Evangélica do Paraná, Universidade Federal do Paraná, Curitiba, PR, Brazil. glaucohrm@gmail.com
authors.forename: Glauco Henrique Reggiani
authors.initials: GH
authors.lastname: Mello
authors.forename: Fabíola Grigoletto
authors.initials: FG
authors.lastname: Lupion
authors.forename: Fernanda Moreira
authors.initials: FM
authors.lastname: Oliveira
authors.forename: Lucas Roskamp
authors.initials: LR
authors.lastname: Bude
authors.forename: Daniel
authors.initials: D
authors.lastname: Wasileweski
authors.forename: Teresa Cristina
authors.initials: TC
authors.lastname: Cavalcanti
authors.forename: Hamilton
authors.initials: H
authors.lastname: Moreira
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002057:Burns, Chemical / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016510:Corneal Neovascularization / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D008297:Male; D011446:Prospective Studies; D011817:Rabbits; D011897:Random Allocation
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab